Results 71 to 80 of about 54,096 (328)
Management of myelofibrosis after ruxolitinib failure
Annals of Hematology, 2020 Myelofibrosis is a BCR-ABL1–negative myeloproliferative neoplasm characterized by anemia, progressive splenomegaly, extramedullary hematopoiesis, bone marrow fibrosis, constitutional symptoms, leukemic progression, and shortened survival.
C. Harrison, N. Schaap, R. Mesa
semanticscholar +1 more source
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
New England Journal of Medicine, 2012 BACKGROUND Treatment options for myelofibrosis are limited. We evaluated the efficacy and safety of ruxolitinib, a potent and selective Janus kinase (JAK) 1 and 2 inhibitor, as compared with the best available therapy, in patients with myelofibrosis ...
C. Harrison +13 more
semanticscholar +1 more source
Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis [PDF]
, 2019 Ruxolitinib, an orally bioavailable and selective inhibitor of Janus kinase 1 (JAK1) and JAK2, significantly reduces splenomegaly and disease-related symptoms in patients with myelofibrosis (MF).
Annunziata, M. +14 more
core +1 more source
Haematologica, 2014 Thrombopoietin-receptor agonists increase platelet counts by stimulating the thrombopoietin receptor. Bone marrow fibrosis has been reported in patients receiving thrombopoietin-receptor agonists.
Waleed Ghanima +6 more
doaj +1 more source
Handbook of Hematologic Malignancies, 2020 Initially, most people with primary myelofibrosis have no signs or symptoms. Eventually, fibrosis can lead to a reduction in the number of red blood cells, white blood cells, and platelets.
Carmelo J. Blanquicett +1 more
semanticscholar +1 more source
Aktualitások a primer myelofibrosis ellátásában | Actualities in the management of primary myelofibrosis [PDF]
, 2016 Absztrakt A primer myelofibrosis a Philadelphia-negatív krónikus myeloid neoplasiák közé tartozó ritka kórkép, amelyre jellemző a cytopeniák és hepatosplenomegalia kialakulása.
Borbényi, Zita +3 more
core +1 more source
Hematology, 2011 AbstractMyelofibrosis (MF), either primary or arising from previous polycythemia vera (PV) or essential thrombocythemia (ET), is the worst among the chronic myeloproliferative neoplasms in terms of survival and quality of life. Patients with MF have to face several clinical issues that, because of the poor effectiveness of medical therapy, surgery or ...
openaire +5 more sources
Clinical Case Reports, 2023 Key Clinical Message Here, we describe a patient with post‐transplant myelofibrosis with chronic graft‐versus‐host disease (GVHD), who showed successful molecular remission with ropeginterferon with 100% donor chimerism without any flare up of GVHD.
Barnali Srivastava +4 more
doaj +1 more source
Degree of fibrosis and its association with angiogenesis in the myelofibrotic bone marrow
Bangabandhu Sheikh Mujib Medical University Journal, 2023 Background: Primary and secondary myelofibrosis has become a global burden due to its increased mortality and morbidity. Angiogenesis is a significant driving force in the development of fibrogenesis in the bone marrow, which leads to myelofibrosis. The
Sadia Afroz +8 more
doaj +3 more sources
Advanced Science, EarlyView.This study uses gut microbiome data to predict corticosteroid response in patients with immune thrombocytopenia (ITP). Fecal samples from 212 patients with ITP are sequenced. Six machine‐learning algorithms are used to train predictive models. The support vector machine‐based model integrated clinical data and selected microbial species, diversities ...
Feng‐Qi Liu +38 more
wiley +1 more source